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CytokinesInterleukin-33 (IL-33) is a recently described member of the IL-1 family of cytokines, which was identiﬁed as
a ligand for the ST2 receptor. Components of the IL-33/ST2 systemwere shown to be expressed in normal and
pressure overloaded human myocardium, and soluble ST2 (sST2) has emerged as a prognostic biomarker in
myocardial infarction and heart failure. However, expression and regulation of IL-33 in human adult cardiac
myocytes and ﬁbroblasts was not tested before. In this study we found that primary human adult cardiac ﬁ-
broblasts (HACF) and human adult cardiac myocytes (HACM) constitutively express nuclear IL-33 that is re-
leased during cell necrosis. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ and IL-1β signiﬁcantly
increased both IL-33 protein and IL-33 mRNA expression in HACF and HACM as well as in human coronary
artery smooth muscle cells (HCASMC). The nuclear factor-κB (NF-κB) inhibitor dimethylfumarate inhibited
TNF-α- and IL-1β-induced IL-33 production as well as nuclear translocation of p50 and p65 NF-κB subunits
in these cells. Mitogen-activated protein/extracellular signal-regulated kinase inhibitor U0126 abrogated
TNF-α-, IFN-γ-, and IL-1β-induced and Janus-activated kinase inhibitor I reduced IFN-γ-induced IL-33 produc-
tion. We detected IL-33 mRNA in human myocardial tissue from patients undergoing heart transplantation
(n = 27) where IL-33 mRNA levels statistically signiﬁcant correlated with IFN-γ (r = 0.591, p = 0.001) and
TNF-α (r = 0.408, p = 0.035) mRNA expression. Endothelial cells in human heart expressed IL-33 as well as
ST2 protein. We also reveal that human cardiac and vascular cells have different distribution patterns of ST2
isoforms (sST2 and transmembrane ST2L) mRNA expression and produce different amounts of sST2 protein.
Both human macrovascular (aortic and coronary artery) and heart microvascular endothelial cells express spe-
ciﬁc mRNA for both ST2 isoforms (ST2L and sST2) and are a source for sST2 protein, whereas cardiac myocytes,
cardiac ﬁbroblasts and vascular SMC express only minor amounts of ST2 mRNA and do not secrete detectable
amounts of sST2 antigen. In accordance with the cellular distribution of ST2 receptor, human cardiac ﬁbroblasts
and myocytes as well as HCASMC did not respond to treatment with IL-33, as recombinant human IL-33 did not
induce NF-κB p50 and p65 subunits nuclear translocation or increase IL-6, IL-8, and monocyte chemoattractant
protein (MCP-1) level in HACF, HACM and HCASMC. In summary, we found that endothelial cells seem to be the
source of sST2 and the target for IL-33 in the cardiovascular system. IL-33 is expressed in the nucleus of human
adult cardiac ﬁbroblasts and myocytes and released during necrosis. Proinﬂammatory cytokines TNF-α, IFN-γ
and IL-1β increase IL-33 in these cells in vitro, and IL-33 mRNA levels correlated with TNF-α and IFN-γ mRNA
expression in human myocardial tissue.
© 2013 Elsevier Ltd. Open access under CC BY license.dicine II, Medical University of
tria. Tel.: +43 1 40400/73500;
Wojta).
Y license.1. Introduction
Interleukin-33 (IL-33) is a recently described member of the IL-1
family of cytokines, which also includes IL-1α, IL-1β and IL-18 [1,2].
IL-33 was identiﬁed as a ligand for the ST2 receptor, which was
known for a long time as an orphan receptor [1]. The transmembrane
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moter system to drive differential mRNA expression [3]. ST2L is nec-
essary for the extracellular effects of IL-33 as IL-33 binds to the
receptor complex composed of ST2L and IL-1R accessory protein
(IL-1RAcP) [4]. Circulating sST2 has emerged as a prognostic biomarker
in patients with myocardial infarction (MI) and heart failure [5–7].
IL-33 is broadly expressed in many tissues but is more restricted at
the level of cell types, and shows a different expression pattern in
comparison to IL-1β and IL-18. Although hematopoietic cells seem
to be the main source of IL-1β and IL-18, only low levels of human
IL-33 mRNA were detected in this cell type [1,2]. Activated dendritic
cells and macrophages are the only haematopoietic cells that show
low quantities of human IL-33 mRNA [1]. Endothelial cells seem to
be the main cell types expressing IL-33 in different organs and tissues
in humans such as lung, colon, kidney, liver, skin [8,9], brain [10], ath-
erosclerotic plaques [11] or adipose tissue [12]. IL-33 is constitutively
expressed in the nucleus of endothelial cells from both small and
large blood vessels [8,9,13,14]. In addition to endothelial cells, also
epithelial cells, keratinocytes, smooth muscle cells (SMC) or ﬁbro-
blasts express IL-33 [1,9,15,16]. Although increased levels of IL-33
protein in tissues and in circulation have been reported in several dis-
eases such as asthma, rheumatologic pathologies, inﬂammatory
bowel and skin diseases [5,15,17,18], reports showing cellular release
of IL-33 after stimulation are scarce [19–22]. According to present
knowledge, IL-33 is speciﬁcally released by necrotic cells but kept in-
tracellular during apoptosis by caspases inactivation [23,24]. This sug-
gests that IL-33 might function as an alarmin belonging to the larger
family of damage-associated molecular pattern (DAMP) molecules
[9,25].
Multiple cell types express transmembrane ST2 on their surface
and can respond to IL-33 [26]. ST2 is expressed on T helper 2
(Th2)-related immune cells such as Th2 cells, mast cells, basophils,
eosinophils, and recently discovered nuocytes, and involved in the ac-
tivation of these cells [1,26,27]. Thus, IL-33 acts as an inﬂammatory
cytokine in Th2-type immune responses during asthma or atopic der-
matitis and seems to be responsible for the host defense against hel-
minth infections [28]. ST2L is also expressed on macrophages, and
IL-33 has been found to amplify the alternative activation of macro-
phages [29]. Also non-haematopoietic cells such as endothelial and
epithelial cells, express ST2 splice variants [30–32]. In human endothe-
lial cells, IL-33 induces inﬂammatory activation through upregulation of
IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), endothelial selectin (E-selectin), increases vascular perme-
ability and promotes angiogenesis [11,30,33].
The regulation of IL-33 expression seems to differ between cell
types. Tumor necrosis factor (TNF)-α, IL-1β, interferon-γ (IFN-γ) or
lipopolysaccharide (LPS) are activators of IL-33 expression in lung,
dermal or synovial ﬁbroblasts, keratinocytes, airway SMC, pancreatic
and hepatic stellate cells, intestinal epithelial cells, central nervous
system glia, and adipocytes [1,15,18,19,34,35]. In human umbilical ar-
tery SMC, IL-33 (referred to in that publication as DVS27) was in-
duced by IL-1α, IL-1β, and IFN-γ, but not by LPS, TNF-α or IL-6 [36].
In neonatal rat cardiac ﬁbroblasts and myocytes, IL-33 expression
was upregulated by biomechanical strain, angiotensin II (Ang II) and
phorbol 12-myristate 13-acetate (PMA); however, neither TNF-α
nor IL-1β induced IL-33 expression in these cells [16]. LPS, but not
IL-1β and TNF-α, upregulated IL-33 in monocytes [37]. In contrast,
endothelial cells respond to proinﬂammatory or angiogenic activation
by TNF-α and IL-1β or vascular endothelial growth factor (VEGF), re-
spectively, with a downregulation of IL-33 expression [8].
However, a possible role of IL-33 and ST2 in the pathogenesis of
cardiovascular diseases is still not well deﬁned. Components of the
IL-33/ST2 systemwere shown to be expressed in normal and pressure
overloaded human myocardium and in coronary artery endothelium
[38] as well as in rat neonatal cardiac myocytes and ﬁbroblasts [16].However, expression and possible regulation of IL-33 in human
adult cardiac myocytes and ﬁbroblasts has not been studied yet.
Therefore, in this study we investigated the cellular origin of IL-33
and ST2 and the regulation of these proteins in human cardiac
myocytes and ﬁbroblasts and cells of the cardiac vasculature in vitro.
In addition we studied the cellular localization of IL-33 and ST2 and
a possible correlation between IL-33 mRNA levels and the inﬂamma-
tory cytokines mRNA levels in human myocardial tissue.
2. Materials and methods
2.1. Cell culture
Primary human adult cardiac ﬁbroblasts (HACF) and primary
human adult cardiac myocytes (HACM) were isolated from ventricu-
lar tissue obtained from explanted recipients' hearts after heart trans-
plantation and cultivated as described by our group previously [39].
Brieﬂy, cells were cultured in minimum essential medium (M199,
Sigma, St. Louis, MO, USA) containing 20% fetal calf serum (FCS),
100 U/ml penicillin, 100 U/ml streptomycin, 0.25 μg/ml fungizone,
and 2 mM L-glutamine (all Cambrex, East Rutherford, NJ, USA) at
37 °C in a humidiﬁed atmosphere of 5% CO2:95% air. Human coronary
artery smooth muscle cells (HCASMC) and human aortic SMC
(HASMC) were isolated by the explant technique from pieces of coro-
nary arteries and aortas, respectively, obtained from patients undergo-
ing heart transplantation. Such SMCwere cultured and characterized as
described [40]. Human coronary artery endothelial cells (HCAEC),
human aortic endothelial cells (HAEC) and human umbilical vein endo-
thelial cells (HUVEC)were isolated bymild collagenase treatment, char-
acterized and cultivated as described [11]. Human heart microvascular
endothelial cells (HHMECs) were isolated from human hearts of pa-
tients undergoing heart transplantation. The study has been reviewed
and approved by the Ethic Committee of theMedical University of Vien-
na, Austria.
2.2. Treatment of the cells
HACF, HACM and HCASMC were incubated in M199 (Sigma)
containing 0.1% bovine serum albumin (BSA, Sigma) for 24 hours
(h) prior to treatment with the respective cytokine. Thereafter, the
medium was replaced with fresh M199 containing 0.1% BSA, and re-
combinant human (rh) TNF-α, rh IL-1β, or rh IFN-γ, all obtained
from R&D Systems (Minneapolis, MN, USA), was added at the concen-
trations indicated for time periods between 3 h and 24 h. Additional-
ly, HACF, HACM and HCASMC were treated with TNF-α, IFN-γ or
IL-1β, each at 2000 U/mL for 24 h, and then necrosis was induced
by subjecting these cells to 5 cycles of freezing to −80 °C and
thawing at 37 °C as described previously [21,37,41]. Furthermore,
cells were pre-incubated for 30 minutes (min) with the NF-κB
inhibitor dimethylfumarate (DMF) [42] (Sigma) at 100 μM before
addition of TNF-α, IL-1β or IFN-γ at the indicated concentrations for
further 24 h. Additionally, cells were pre-incubated for 30 min with
the mitogen-activated protein/extracellular signal-regulated kinase
(MEK) inhibitor U0126 (Promega, Madison, WI, USA) at 10 μM or
the janus-activated kinase (JAK) 1 and 2 inhibitor JAK inhibitor I
(Calbiochem, Merck, Darmstadt, Germany) at 10 μM before addi-
tion of TNF-α, IL-1β or IFN-γ for further 24 h. In another set of ex-
periments, HACF, HACM and HCASMC were incubated with rh IL-33
(R&D Systems) at concentrations of 100, 10 or 1 ng/mL or with rh
IL-1β at 10 ng/mL (R&D Systems) for time periods between 3 h and
24 h.
2.3. Human tissue
Human heart tissue was obtained from the left ventricle of
explanted hearts from 27 patients suffering from cardiomyopathy
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isolation. All human material was obtained and processed according to
the recommendations of the hospital's Ethics Committee.
2.4. Total RNA puriﬁcation and cDNA preparation
Cells were treated as described (for IL-33 mRNA determination) or
left untreated (for measurement of basal total ST2, ST2L, or sST2 mRNA
expression), supernatants were removed and total cellular RNAwas iso-
lated using High Pure RNA Isolation Kit (Roche, Basel, Switzerland)
according to the manufacturer's instructions. Frozen human myocardial
tissue was homogenized using a ball mill (Retsch, Haan, Germany), and
mRNA was isolated using High Pure RNA Tissue Kit (Roche). The total
RNA amount was measured using NanoDrop (Thermo Scientiﬁc,
Barrington, IL, USA). Reverse transcription was performed using
Transcriptor First Strand cDNA Synthesis Kit (Roche). For PCR of ST2
isoforms, cDNA was additionally eluted with MinElute PCR Puriﬁcation
Kit (QIAGEN GmbH, Hilden, Germany).
2.5. RealTime-PCR
RealTime-PCR was performed using LightCycler® TaqMan®
Master (Roche) according to the manufacturer's instructions. Primers
were designed using the Roche UniversalProbeLibrary Assay Design
Centre (http://www.universalprobelibrary.com/). Please see Supple-
mental Table 1 for detailed information on primers used. The ampliﬁ-
cation conditions consisted of an initial incubation at 95 °C for
10 min, followed by 45 cycles of 95 °C for 10 s, 63 °C for 20 s and
72 °C for 6 s and a ﬁnal cooling to 40 °C. Data was analyzed using
LightCycler Software Version 3.5 (Roche).
2.6. Protein determination
IL-33 protein in cell lysates and cell culture supernatants and sST2
protein in cell culture supernatants was measured by speciﬁc
enzyme-linked immunosorbent assays (ELISAs) (both from R&D
Systems). Cells were permeabilized with PBS containing 0.1% Triton
X-100 (Sigma). IL-6, IL-8 and MCP-1 antigen in cell culture superna-
tants was measured by speciﬁc ELISAs using monoclonal antibodies
(all from Bender MedSystems, Vienna, Austria).
2.7. Nuclear extraction and analysis of NF-κB/DNA binding
HACM, HACF or HCASMC were treated with TNF-α or IL-1β (each
at 2000 U/mL) for 60 min with or without pre-incubation for 30 min
with DMF 100 μM. Additionally, HACM, HACF or HCASMC were incu-
bated for 15, 30 or 60 min with or without rh IL-33 (R&D Systems) at
a concentration of 100 ng/mL. Preparation of nuclear extracts was
performed using a Nuclear Extract Kit (Active Motif, Rixensart, Belgium)
according to the manufacturer's instructions. Quantiﬁcation of p50 and
p65 NF-κB subunits in nuclear extracts of such treated cells was
performed using the ELISA-based TransAMTM NF-κB Family kit (Active
Motif) as described previously [43].
2.8. Immunoﬂuorescence analysis of IL-33 in cultured cells
HACF, HACM and HCASMC were seeded on Permanox chamber
slides (Nunc Inc., Neparville, IL, USA). Conﬂuent monolayers were
left untreated or stimulated with rh TNF-α, rh IFN-γ or rh IL-1β,
each at 2000 U/mL. After incubation for 24 h the cells were washed
with PBS and ﬁxed with 3.7% paraformaldehyde. The cells were
washed again and then permeabilized with 0.1% Triton X-100
(Sigma) in PBS for 20 min at room temperature, washed in PBS, and
blocked with 5% BSA (Sigma) in PBS for 30 min. Subsequently, cells
were washed again and incubated overnight with primary mouse
monoclonal anti-IL-33 antibody (clone Nessy-1; Alexia Biochemicals,Enzo Life Sciences AG, Lausen, Switzerland) at 4 °C at a dilution of
1:1000 in diluent solution for primary antibody (DAKO, North America,
Inc., CA, USA, catalogue number S3022). The same diluent solution
without primary antibody was used as a negative control. After
washing, a 1:1000 dilution of Alexa Fluor-488 goat anti-mouse immu-
noglobulin G (IgG) (Invitrogen-Molecular Probes, Paisley, UK) in dilu-
ent solution for secondary antibody (DAKO, catalogue number S0809)
was incubated with the cells for 1 h at room temperature in the dark.
Afterﬁnalwashes, cells weremounted using Vectashieldmountingme-
dium with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories
Inc., Burlingame, CA, USA) for nuclear counter staining and sealed
with nail polish. Fluorescence was assessed by microscopy with a
confocal laser scanning microscope (LSM-700; Carl Zeiss, Oberkochen,
Germany) with 40× lens using ZEN 2009 software.
2.9. Immunoﬂuorescence analysis of IL-33 and ST2 in explanted hearts
Parafﬁn-embedded sections were deparafﬁnised and then boiled
for antigen retrieval in citrate buffer (Dako). Sections were blocked
with Dako blocking solution for 30 min at room temperature. The fol-
lowing primary antibodies were used: mouse monoclonal anti-IL33
antibody in dilution 1:500 (clone Nessy-1; Enzo Life Sciences); rabbit
polyclonal anti-ST2 (IL1RL1) antibody 1:100 (Sigma); goat polyclonal
anti-troponin I antibody 1:100 (AbD serotec); rabbit polyclonal
anti-Von Willebrand Factor (vWF) antibody 1:500 (Dako); mouse
monoclonal anti-smooth muscle actin antibody 1:100 (Dako). Prima-
ry antibodies were incubated overnight at 4 °C. After extensive wash-
ing in PBS, slides were incubated with secondary antibodies for 1 h at
room temperature in the dark. Secondary antibodies were Alexa
Fluor-488 rabbit anti-goat IgG (Invitrogen-Molecular Probes), Alexa
Fluor-546 goat anti-mouse and goat anti-rabbit IgG and Alexa
Fluor-633 goat anti-rabbit IgG. All antibodies were diluted in PBS
containing 0.1% Triton X-100. Nuclear counter staining with DAPI
(1 μg/ml; Sigma) for 10 min at room temperature was performed.
Tissue sections were analyzed with a confocal laser scanning micro-
scope (LSM-780; Carl Zeiss) using ZEN 2010 software.
2.10. Statistics
Values are expressed as mean ± SD. Data were compared by
ANOVA. IL-33, TNF-α, IFN-γ, IL-1β mRNA expression data in human
myocardial tissue were correlated by using a Spearman correlation
(SPSS 18.0, Chicago, IL, USA). Values of p ≤ 0.05 were considered
signiﬁcant.
3. Results
3.1. IL-33 is constitutively expressed in human cardiac ﬁbroblasts and
cardiac myocytes
As can be seen from Fig. 1, HACF (Fig. 1A) and HACM (Fig. 1B) ex-
press IL-33 at protein level as determined by immunoﬂuorescence
analysis. IL-33 is expressed in the nucleus of these cells as shown by
the co-staining with DAPI (Figs. 1A and B). We also determined
IL-33 protein in permeabilized HACF and HACM by ELISA (Figs. 2B,
D, F). HCASMC also express IL-33 protein under basal conditions as
determined by immunoﬂuorescence analysis (Fig. 1C) and ELISA
(Figs. 2B, D, F).
3.2. Pro-inﬂammatory cytokines increase IL-33 expression in human
cardiac ﬁbroblasts, cardiac myocytes and vascular smooth muscle cells
via NF-κB, MEK or JAK1/2 pathways
We found that TNF-α, IFN-γ, and IL-1β at a concentration of
2000 units/ml (U/mL) increased intracellular IL-33 in HACF
(Fig. 1A), HACM (Fig. 1B) and HCASMC (Fig. 1C), as determined by
A HACF
nuclei IL-33 merged
Co
TNF
IFN
B HACM
nuclei IL-33 merged
Co
TNF
IFN
IL-1
C
HCASMC
nuclei IL-33 merged
Co
TNF
IFN
IL-1
IL-1
Fig. 1. Expression of interleukin (IL)-33 in human cardiac ﬁbroblasts, cardiac myocytes and coronary artery smooth muscle cells. Human adult cardiac ﬁbroblasts (HACF), human
adult cardiac myocytes (HACM), and human coronary artery smooth muscle cells (HCASMC) were incubated for 24 hours (h) in the absence (control, Co) or presence of tumor
necrosis factor (TNF)-α, interferon (IFN)-γ or IL-1β (each at 2000 Units/mL (U/mL)). Staining for IL-33 in HACF (A), HACM (B) and HCASMC (C) was performed as described in
“Materials and methods.” Original magniﬁcation ×400. Staining was representative for 2 different donors for each cell types.
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incubated for 24 h with TNF-α, IFN-γ or IL-1β at indicated concentra-
tions, we found a concentration-dependent increase in intracellular
IL-33 protein in these cells (Figs. 2A, C, E). At the highest tested con-
centration, TNF-α (Fig. 2A) induced IL-33 protein up to 3.5-, 11.5- and
8.2-fold, IFN-γ (Fig. 2C) up to 5.5-, 23.1- and 8.9-fold, and IL-1β
(Fig. 2E) up to 5.1-, 3.3- and 3.7-fold in HACF, HACM and HCASMC,
respectively. Stimulatory effects of TNF-α, IFN-γ and IL-1β at
2000 U/mL each on IL-33 protein expression in additional donors
are shown in Supplemental Table 2. In all three cell types TNF-α
and IFN-γ induced statistically signiﬁcant (p ≤ 0.05) upregulation
of IL-33 protein at concentrations between 2000 and 100 U/mL
(Figs. 2A, C). IL-1β statistically signiﬁcant (p ≤ 0.05) upregulated
IL-33 protein at concentration between 2000 and 5 U/mL in HACF
and HCASMC (Fig. 2E). In HACM IL-33 was statistically signiﬁcant
(p ≤ 0.05) upregulated after 24 h of incubation with 2000 and
500 U/mL of IL-1β (Fig. 2E). When HACF, HACM and HCASMC weretreated with TNF-α, IFN-γ, and IL-1β for 3 h, 6 h, 12 h and 24 h
IL-33 mRNA was increased by TNF-α up to 6.6-, 3.1- and 4-fold, by
IFN-γ up to 3.4-, 7.6- and 20.7-fold, and by IL-1β up to 15.7-, 2.0-
and 4.6-fold in the respective cell type (Figs. 2B, D, F).
The NF-κB inhibitor DMF [42] at 100 μM inhibited TNF-α and
IL-1β-induced nuclear translocation of the p65 NF-κB subunit in all
three types of the cells (Fig. 3A). Similar results were seen for the
NF-κB subunit p50 (data not shown). Furthermore, DMF at the
same concentration reduced TNF-α and IL-1β-induced increase in
IL-33 protein to control levels in human cardiac ﬁbroblasts, myocytes
and vascular smooth muscle cells (Fig. 3B). In contrast, DMF did not
inﬂuence IFN-γ-induced IL-33 production in any type of the cells
used (data not shown). However, MEK inhibitor U0126 at 10 μM
(Fig. 3C) or JAK inhibitor I (a JAK 1 and 2 inhibitor) at 10 μM
(Fig. 3D) abrogated IFN-γ-induced IL-33 production in these cells.
U0126 also abrogated TNF-α and IL-1β-indcued IL-33 expression
(Fig. 3C).
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Fig. 2. Effects of tumor necrosis factor (TNF)-α, interferon (IFN)-γ and interleukin (IL)-1β on intracellular IL-33 protein expression and IL-33 mRNA in human cardiac ﬁbroblasts, cardiac
myocytes and coronary artery smooth muscle cells. HACF, HACM, and HCASMCwere incubated for 24 h in the absence or presence of TNF-α (A), IFN-γ (C) or IL-1β (E) at indicated con-
centrations. IL-33 protein in the cell lysates was measured by a speciﬁc ELISA as described in “Materials and methods”. Each experiment was performed in triplicates. Values are given as
pg/10,000 cells/24 h and represent mean ± SD. Experiments were performed 4 times with cells obtained from 3 different donors. *p ≤ 0.05 as compared to the control in HACF;
§p ≤ 0.05 as compare to the control inHACM; $p ≤ 0.05 as compared to the control inHCASMC. HACF, HACM, andHCASMCwere incubated for 3, 6, 12 or 24 h in the absence or presence
of TNF-α (B), IFN-γ (D) or IL-1β (F) (each at 2000 Units/mL (U/mL)). mRNAwas prepared and RealTime-PCRwith primers speciﬁc for IL-33 or glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was performed as described in “Materials and methods”. IL-33 mRNA levels were normalized according to the GAPDH mRNA levels. Each experiment was performed in
triplicates. Values are given as x-fold of control, which was set as 1, and represent mean ± SD. Experiments were performed 2 times with cells obtained from 2 different donors.
*p ≤ 0.05 as compared to the controls in HACF; §p ≤ 0.05 as compared to the controls in HACM; $p ≤ 0.05 as compared to the controls in HCASMC.
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ﬁbroblasts, myocytes and coronary artery smooth muscle cells
In culture supernatants of undamaged HACF (Fig. 4A), HACM
(Fig. 4C) andHCASMC (Fig. 4E)we could not detect IL-33 protein neither
under basal conditions nor after incubation with TNF-α, IFN-γ, or IL-1β.
However, when these cells underwent necrosis by repeated freeze-
thawing, detectable amounts of IL-33 were released into cell culture su-
pernatants in these cells which were signiﬁcantly higher when the cells
had been treated prior to induction of necrosis with TNF-α, IFN-γ, or
IL-1β as compared to the respective controls (Figs. 4B, D, and F). Inparallel, in necrotic HACF, HACM and HCASMC intracellular IL-33 con-
centrations were reduced (Figs. 4B, D, and F).
3.4. Expression of IL-33 mRNA in human myocardial tissue correlates
with mRNA for pro-inﬂammatory cytokines
To test if our in vitro results are also relevant for the in vivo situa-
tion, we measured IL-33, TNF-α, IFN-γ and IL-1βmRNA expression in
tissue samples obtained from left ventricles from explanted hearts of
patients (n = 27) undergoing heart transplantation. We detected
IL-33 mRNA in all samples and found that IL-33 mRNA positively
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Fig. 3. Nuclear factor-κB (NF-κB) inhibitor dimethylfumarate (DMF) abrogated TNF-α- and IL-1β-induced nuclear translocation of NF-κB p65 subunit and IL-33 expression and
mitogen-activated protein/extracellular signal-regulated kinase (MEK) or janus-activated kinase (JAK) 1 and 2 inhibitors reduced TNF-α, IFN-γ, or IL-1β-induced IL-33 expression
in human adult cardiac ﬁbroblasts (HACF), cardiac myocytes (HACM), or coronary artery smooth muscle cells (HCASMC). HACF, HACM, and HCASMC were pre-incubated for 30 min
with DMF at 100 μM. Subsequently, these cells were treated with TNF-α- or IL-1β (each at 2000 U/mL) for 60 min. Preparation of nuclear extracts and quantiﬁcation of p65 NF-κB
subunit (A) were performed as described in “Materials and methods”. Values are given as OD492 nm and represent mean ± SD. Experiments were performed 2 times with cells
obtained from 2 different donors for each cell types. HACF, HACM, and HCASMC were ﬁrst pre-incubated with DMF at 100 μM for 30 min and then treated with TNF-α- or IL-1β
for 24 h (B). HACF, HACM, and HCASMC were ﬁrst pre-incubated with U0126 at 10 μM for 30 min and then treated with TNF-α, IFN-γ or IL-1β for 24 h (C). HACM were ﬁrst
pre-incubated with JAK inhibitor I at 10 μM for 30 min and then treated with IFN-γ at 2000 U/mL for 24 h (D). IL-33 protein in the cell lysates was measured by a speciﬁc
ELISA as described in “Materials and methods”. Each experiment was performed in triplicates. Values are given in IL-33 (units) as % of control, which was set as 100% and represent
mean ± SD. Experiments were performed 3 times with cells obtained from 3 different donors. *p ≤ 0.05 as compared to untreated control in HACF; **p ≤ 0.05 as compared to
TNF-α, or IL-1β- or IFN-γ-treated cells in HACF; §p ≤ 0.05 as compare to untreated control in HACM; §§p ≤ 0.05 as compared to TNF-α, or IL-1β- or IFN-γ-treated cells in
HACM; $p ≤ 0.05 as compared to untreated control in HCASMC; $$p ≤ 0.05 as compared to TNF-α, or IL-1β- or IFN-γ-treated cells in HCASMC.
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Fig. 5A) and TNF-α (r = 0.408, p = 0.035; Fig. 5B) mRNA levels, re-
spectively. We also found a weak positive correlation (r = 0.344) be-
tween IL-33 and IL-1β mRNA expression. However, this correlation
did not reach statistical signiﬁcance (p = 0.092; data not shown).3.5. Endothelial cells but not cardiac myocytes, cardiac ﬁbroblasts and
smooth muscle cells predominantly express the IL-33 receptor ST2 and
secrete sST2
In order to determine which cell types are a possible target for
IL-33 or a source of sST2 in the human cardiovascular system we
screened different cell types such as cardiac myocytes and ﬁbroblasts
and vascular smooth muscle cells and endothelial cells from various
vascular beds for the expression of total ST2 mRNA, ST2L mRNA and
sST2 mRNA as well as for the secretion of sST2 antigen. As can be
seen from Fig. 6, HACF, HACM, HASMC or HCASMC, respectively, ex-
press only minor amounts of speciﬁc mRNA for total ST2 (Fig. 6A),
ST2L (Fig. 6B) or sST2 (Fig. 6C). In comparison to these cell types
macrovascular (HUVEC, HCAEC, HAEC) and microvascular (HHMEC)
endothelial cells express high levels of mRNA speciﬁc for the respec-
tive receptor isoforms (Figs. 6A–C). Furthermore, using the ELISA de-
scribed under “Materials and methods” (lower limit of detection:31 pg/ml), sST2 protein could not be detected in the supernatants
of HACF, HACM, HASMC or HCASMC (Table 1). In contrast,
macrovascular (HUVEC, HCAEC, HAEC) and microvascular (HHMEC)
endothelial cells secreted sST2 antigen into the respective cell culture
supernatant (Table 1).3.6. In human cardiac myocytes, cardiac ﬁbroblasts and vascular smooth
muscle cells, IL-33 has neither an effect on NF-κB nuclear translocation
nor on IL-6, IL-8 and MCP-1 production
Neither HACF, nor HACM nor HCASMC responded to IL-33
(Supplemental Fig. 1). IL-33 at 100 ng/mL did not induce nuclear
translocation of NF-κB p50 (Supplemental Fig. 1A) and p65 (Supple-
mental Fig. 1B) subunits between 15 min and 60 min of incubation
in these cells. When HACF, HACM or HCASMC were incubated with
IL-33 at concentrations of 1, 10 or 100 ng/mL for 24 h, no changes
in IL-6 (Supplemental Fig. 1C), IL-8 (Supplemental Fig. 1D) or
MCP-1 (Supplemental Fig. 1E) protein production or mRNA expres-
sion (data not shown) were observed. In accordance with recently
published results from our group in the same set of experiments, rh
IL-33 used at the same concentrations signiﬁcantly upregulated IL-6,
IL-8 and MCP-1 as well as NF-κB p50 and p65 nuclear translocation
in HUVEC and HCAEC [11]. In contrast to IL-33, IL-1β at 10 ng/mL
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Fig. 4. Interleukin (IL)-33 is released during necrosis from human cardiac ﬁbroblasts, cardiac myocytes and coronary artery smooth muscle cells. HACF (panels A and B), HACM
(panels C and D), and HCASMC (panels E and F) were incubated for 24 h in the absence or presence of TNF-α, IFN-γ or IL-1β (each at 2000 U/mL). Afterward, cells were left
undamaged or necrosis was induced by repeated freeze-thawing. IL-33 protein in the cell culture supernatants and cell lysates was measured by a speciﬁc ELISA as described in
“Materials and methods”. Each experiment was performed in triplicates. Values are given as pg/10,000 cells/24 h and represent mean ± SD. Experiments were performed 2
times with cells obtained from 2 different donors. Cell culture supernatants — ﬁlled bars; cell lysates — open bars. *p ≤ 0.05 as compared to the controls in undamaged cells
(cell lysate); §p ≤ 0.05 as compared to the controls in necrotic cells (cell culture supernatants); $p ≤ 0.05 as compared to the controls in necrotic cells (cell lysate).
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mental Fig. 2B) and MCP-1 (Supplemental Fig. 2C) in HACF, HACM
and HCASMC ().3.7. Cellular localization of IL-33 and ST2 protein in human heart
As can be seen from Fig. 7A, nuclear IL-33 and membrane
bound ST2 are expressed on the same cells in blood vessels in the
heart. Co-staining with vWF or CD31 as speciﬁc markers of endothe-
lial cells showed that both IL-33 (Figs. 7B and C) and ST2 (Fig. 7D)
are strongly expressed by endothelial cells in the vessel wall. IL-33
protein is also expressed by cardiac myocytes (Supplemental
Fig. 3A, 3C, and Supplemental Fig. 5) and smooth muscle cells
(Supplemental Fig. 4). Supplemental Fig. 3A shows that also white
blood cells are positive for IL-33 protein (indicated with the arrow)
as already described previously [1]. However, ST2 protein expression
is absent in SMA-positive cells (Supplemental Fig. 4A) and troponin-
positive cells are only weakly positive for ST2 protein (SupplementalFig. 3B and 3C) in human heart conﬁrming our in vitro ﬁndings
(Figs. 1 and 6).
4. Discussion
IL-33 was found recently in endomyocardial biopsies from pa-
tients with aortic valve stenosis and congestive heart failure [38]. In
addition IL-33 is expressed by endothelial and smooth muscle cells
[1,8,9,11,14,15,31,38]. We show here for the ﬁrst time that human
adult cardiac ﬁbroblasts and myocytes constitutively express IL-33
in vitro. In our study IL-33 protein was localized in the nucleus but
could not be detected in the supernatants of cultured undamaged
cardiac myocytes and ﬁbroblasts. Moreover, we show that the
proinﬂammatory cytokines TNF-α, IFN-γ and IL-1β upregulate IL-33
on the protein as well as on the mRNA level in cardiac myocytes, ﬁ-
broblasts and vascular smooth muscle cells. The concentrations of
TNF-α, IFN-γ and IL-1β inducing an increase in IL-33 production in
those cells in vitro were higher than plasma concentrations of these
cytokines measured in patients suffering from various cardiovascular
Fig. 5. IL-33 mRNA correlates with IFN-γ and TNF-αmRNA expression in human myo-
cardial tissue. RNA was isolated from tissue samples obtained from left ventricles from
explanted hearts of patients (n = 27) undergoing heart transplantation. IL-33, IFN-γ
and TNF-α mRNA and mRNA for GAPDH was determined by RealTime-PCR as de-
scribed in “Materials and methods”. mRNA levels of IL-33, IFN-γ and TNF-α were cor-
related after adjustment for GAPDH.
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Fig. 6. Expression of ST2 receptor isoforms in human cardiac cells and in vascular cells.
Human adult cardiac ﬁbroblasts (HACF), human adult cardiac myocytes (HACM),
human aortic smooth muscle cells (HASMC), human coronary artery smooth muscle
cells (HCASMC), human umbilical vein endothelial cells (HUVEC), human coronary ar-
tery endothelial cells (HCAEC), human aortic endothelial cells (HAEC), and human
heart microvascular endothelial cells (HHMEC) were left untreated. mRNA was pre-
pared, cDNA was additionally eluted with MinElute PCR Puriﬁcation Kit and equal
amount of cDNA was used for RealTime-PCR with primers speciﬁc for totalST2 (A),
ST2L (B), or sST2 (C) as described in “Materials and methods”. Values are given as
x-fold of HAEC, which was set as 1 and represent mean ± SD. Experiments were
performed with cells obtained from at least 3 different donors for each type of cells.
23S. Demyanets et al. / Journal of Molecular and Cellular Cardiology 60 (2013) 16–26diseases such as heart failure, myocardial infarction, or unstable angi-
na [44–46]. It should be taken into consideration, however, that in an
in vivo setting these cytokines might accumulate at sites of inﬂamma-
tion or tissue damage leading to higher local concentrations of these
biomolecules in the affected tissue as compared to systemic levels
in the plasma. In that respect it is of interest that higher levels of
TNF-α were found in hearts from patients suffering from end stage
heart failure as compared to plasma levels of TNF-α seen in such pa-
tients. In addition, the respective levels of the cytokine were dramat-
ically increased when compared to levels in healthy controls [47].
Furthermore it should be noted, that the concentrations of TNF-α,
IFN-γ and IL-1β used here in our cell culture experiments are in the
same range as concentrations of these cytokines used in other cell
culture studies performed by us and others [39,40,48] In our in vitro
experiments, similar to other proteins investigated in earlier studies,
we noted a donor-dependent variability of basal and cytokine-
induced IL-33 expression in the cells tested which might reﬂect vari-
ability in the biosynthesis of IL-33 amongst different individuals. In
that respect it is of interest that IL-33 plasma levels varied from 5.4
to 17893.0 pg/mL in patients with myocardial infarction [49]. Itshould be emphasized, however, that all cells responded with a sig-
niﬁcant increase in IL-33 in response to TNF-α, IFN-γ and IL-1β. In
agreement with our results IL-33 expression was previously shown
to be induced by proinﬂammatory stimuli in various cell types such
as dermal, lung or synovial ﬁbroblasts and human airway smooth
muscle cells [1,15,50] as well as keratinocytes, stellate cells, intestinal
epithelial cells, astrocytes, and adipocytes [1,15,18,19,34,35]. In
human umbilical artery smooth muscle cells IL-33 was induced by
IL-1 and IFN-γ, but not by TNF-α [36]. In contrast to our ﬁndings,
however, TNF-α and IL-1β did not induce IL-33 expression in rat neo-
natal cardiac myocytes and ﬁbroblasts [16]. This could reﬂect a spe-
cies speciﬁc and/or development-dependent regulation of IL-33.
As shown by immunohistochemical analysis of hearts of the pa-
tients suffering from cardiomyopathy endothelial cells in the heart
express nuclear IL-33 as well as its membrane-bound receptor ST2,
whereas cardiac myocytes and vascular smooth muscle cells in the
heart stained positive for IL-33 only and were weak positive or nega-
tive, respectively, for ST2 conﬁrming our in vitro observations. In
explanted hearts of patients undergoing heart transplantation IL-33
Table 1
Secretion of sST2 by human cardiac and vascular cells.
Cell type sST2, pg/10,000 cells/24 h
HUVEC 1308 ± 86
HAEC 119 ± 174
HCAEC 219 ± 113
HHMEC 28 ± 10
HACF n.d.
HACM n.d.
HCASMC n.d.
HASMC n.d.
Conﬂuent monolayers of human umbilical vein endothelial cells
(HUVEC), human aortic endothelial cells (HAEC), human coronary
artery endothelial cells (HCAEC), human heart microvascular
endothelial cells (HHMEC), human adult cardiac ﬁbroblasts (HACF),
human adult cardiac myocytes (HACM), human coronary artery
smooth muscle cells (HCASMC), and human aortic smooth muscle
cells (HASMC) were cultivated under respective culture conditions for
24 h untreated. Cell culture supernatants were collected and sST2
protein was measured using speciﬁc ELISA as described in “Materials
and methods”. Values are given as pg/10,000 cells and represent
mean ± SD in case of HUVEC, HCAEC and HAEC. Experiments were
performed with cells obtained from 4 different donors for HUVEC,
HACF, HACM, HCASMC, and obtained from 3 different donors for
HASMC, HCAEC, HAEC, and HHMEC. N.d. — not detectable.
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the inﬂammatory mediators TNF-α and IFN-γ, respectively. It is of in-
terest that previously a positive correlation between IL-33 and TNF-αDAPI IL-33
A
DAPI IL-33
B
C
DAPI ST2
D
Fig. 7. IL-33 and ST2 protein in endothelial cells in human heart. Confocal immunoﬂuorescen
and von Willebrand factor (vWF, B and C), and ST2 and CD31 (D). Original magniﬁcation ×
10 μm (C).expression in the lung tissues in patients with asthma has been de-
scribed suggesting a role of IL-33 in the pathogenesis of that disease
[15].
Numerous studies have investigated pathways activated by IL-33
in different cells [26]. In contrast, little is known about the regulation
of IL-33 expression by various cytokines. Different signaling pathways
are activated by TNF-α, IL-1β or IFN-γ [51,52]. In our study, the ef-
fects of TNF-α and IL-1β on IL-33 expression were mediated via
NF-κB and MEK whereas the increase in IL-33 expression by IFN-γ
was mediated through MEK and JAK 1 and 2 pathways. In agreement
with our results it was shown, that the induction of IL-33 expression
by IL-1 in human pancreatic stellate cells was also mediated via NF-κB
[34]. Furthermore, similar to our results, IFN-γ-induced expression of
IL-33 in human epidermal keratinocytes was found to be MEK- and
JAK 1- and 2-dependent [53].
It is still a matter of controversy if and how IL-33 is secreted by
undamaged cells. We could not detect any secreted IL-33 protein in
the supernatant of undamaged unstimulated human cardiac ﬁbro-
blasts and cardiac myocytes. Recently, it was shown that PMA in-
duced the secretion of IL-33 in rat neonatal cardiac ﬁbroblasts [16].
As described above, TNF-α, IFN-γ or/and IL-1β were shown to induce
intracellular accumulation of IL-33, but not its extracellular secretion,
from intestinal epithelial cells [18], synovial ﬁbroblasts [50], pancre-
atic stellate cells [34] and adipocytes/preadipocytes [35]. These ob-
servations are consistent with ours in human cardiac ﬁbroblasts
and myocytes, as we did not detect IL-33 protein in the supernatant
of undamaged TNF-α-, IFN-γ-, or IL-1β-treated cells. Nuclear IL-33ST2 merge
vWF merge
CD31 merge
ce images of blood vessels in human heart tissue. Co-staining of IL-33 and ST2 (A), IL-33
630. C, cropped region of B with factor 1.5. Scale bar = 20 μm (A, B, D). Scale bar =
25S. Demyanets et al. / Journal of Molecular and Cellular Cardiology 60 (2013) 16–26expression was previously found in endothelial and epithelial cells in
normal, chronically inﬂamed, and tumor tissues [8,9,11,14,18], pan-
creatic stellate cells [34], keratinocytes [54], and astrocytes [19]. Der-
mal and pulmonary ﬁbroblasts showed nuclear IL-33 expression in
patients with systemic sclerosis [54]. In human monocytes the IL-33
protein was mainly found in the cytoplasm [37]. In contrast, different
murine and human primary cells or cell lines secrete IL-33 after stim-
ulation with LPS, PMA plus ionomycin, Toll-like receptor (TLR)7 or
TLR1/2 agonists, IgE, or infection with inﬂuenza A virus [19–22,55].
Activated murine macrophages and dendritic cells release IL-33 pro-
tein following cellular necrosis [24,37] and noradrenaline and adren-
aline enhanced IL-33 production by necrotic dendritic cells upon LPS
stimulation [56]. Therefore, IL-33 is recognized as a dual function cy-
tokine that acts either intracellular to regulate gene transcription or
extracellular via binding to its receptor ST2L [9,57].
Upon cell injury, endogenous danger signals, so-called DAMPs, are
released by necrotic cells [25]. IL-33 is recognized as a key danger sig-
nal released by necrotic structural cells [23,24,41,57]. When human
cardiac cells as well as coronary artery smooth muscle cells were
subjected to necrosis in our study, IL-33 was released into cell culture
supernatants. Previously, IL-33 was shown to be released from ne-
crotic cells of stromal origin such as mouse embryonal ﬁbroblasts
and smooth muscle cells [41]. IL-33 is also released extracellular
after endothelial cell damage or injury [23]. Upon release, IL-33 was
shown to be recognized by different immune cells such as mast
cells, basophils, eosinophils, nuocytes and Th2 cells, which produce
proinﬂammatory mediators in response to IL-33 [1,26,27,41]. Extra-
cellular IL-33 can also induce endothelial activation by upregulation
of adhesion molecules ICAM-1, VCAM-1, E-selectin and induction of
adhesion of blood leukocytes to activated endothelial cell monolayers
[11]. Thus, it is possible to speculate that IL-33 could be released dur-
ing necrosis or damage from human adult cardiac cells and drive the
immune answer of haematopoietic cells or modulate functions of
neighboring cells in a paracrine manner. It should also be noted that
recently it was shown that IL-33 is released from ﬁbroblasts following
mechanical strain [58]. If such a mechanism is also operative in cardiac
cells, one might speculate that IL-33 might also play a pathophysiolog-
ical role in cardiovascular diseases such as heart failure characterized by
mechanical strain impacting on the cardiac tissue.
In order to identify possible cellular targets for IL-33 produced by
cardiac myocytes and ﬁbroblasts in the cardiovascular system we
screened different cell types isolated from human heart and adjacent
vascular beds for the presence of speciﬁc mRNA for ST2 isoforms and
for the production of sST2 protein. We show that macrovascular endo-
thelial cells isolated from aorta and coronary arteries andmicrovascular
endothelial cells isolated frommyocardial tissue express total ST2, ST2L
and sST2mRNA and secrete sST2. In contrast, cardiacmyocytes and car-
diac ﬁbroblasts or vascular smooth muscle cells from coronary arteries
or aorta express only minor levels of total ST2, ST2L and sST2 mRNA
and do not secrete detectable amount of sST2 antigen. In agreement
with our results sST2mRNA and protein and ST2LmRNAwas previous-
ly demonstrated by others in both vein and arterial endothelial cells
as well as in microvascular endothelial cells from lung blood vessels
in humans [30–32,38,59]. A study by Bartuneck et al. found no
transmyocardial sST2 gradient,which argues against cardiac production
of serum sST2 [38]. Similar to our ﬁndings Mildner et al. detected nei-
ther sST2mRNA expression nor protein production in human cardiac ﬁ-
broblasts. However, in the same paper the group showed sST2 mRNA
expression and sST2 protein production in human cardiac myocytes
[32]. These latter differences could reﬂect differences in cell culture
conditions. Both sST2 and ST2L mRNA were detected in neonatal rat
cardiac cells [16,60], which could indicate a species-speciﬁc and/or
development-depending cellular distribution of ST2.
Upon interactionwith its receptor IL-33was shown to activate NF-κB
in different cell types [1,11]. Moreover, IL-33 induces inﬂammatory acti-
vation, as shown by increased IL-6, IL-8 or MCP-1 production, in celltypes which express ST2L such as endothelial cells, epithelial cells,
mast cells, basophils and eosinophils [11,26,30]. Consistent with the
scarce expression of ST2L in human cardiac myocytes and ﬁbroblasts
and in vascular smooth muscle cells in our study, neither NF-κB nuclear
translocation nor IL-6, IL-8 or MCP-1 production was affected in such
cells treated with rh IL-33 in concentrations previously shown to be ef-
fective in in vitro studies by us and others [11,30,33]. Recently, rat adult
cardiac ﬁbroblasts were shown to express ST2 and responded to treat-
ment with IL-33 with increased IL-6 and MCP-1 production and activa-
tion of the NF-κB p65 subunit [61], which again supports the notion of
species-speciﬁc differences in ST2 expression and in the cellular re-
sponse to IL-33.
In conclusion, we found that IL-33 is expressed by human adult
cardiac myocytes and ﬁbroblasts and by human coronary artery
smooth muscle cells and that the cytokine is present in the nucleus
of these cells. The IL-33 receptor ST2 shows a distinct expression pat-
tern in the heart as it is predominantly expressed by endothelial cells
of the cardiac vasculature. IL-33 is upregulated by TNF-α, IFN-γ and
IL-1β and is released during necrosis of human cardiac and smooth
muscle cells. In human myocardial tissue from hearts of patients un-
dergoing heart transplantation, endothelial cells are the main cell
type expressing both IL-33 as well as its receptor ST2. Furthermore
IL-33 expression correlates positively with that TNF-α and IFN-γ, re-
spectively, in such myocardial tissue. Possible pathophysiological
consequences of the regulated expression of the alarmin IL-33 and
the cell speciﬁc distribution of its receptor ST2 in the human heart
e.g. following injury and subsequent necrosis warrant subsequent in-
vestigations to further test our hypothesis in the in vivo setting.
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